MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
Levitee Labs Announces DTC Eligibility Approval
Levitee Labs announces that its shares are now eligible for clearing through the DTC.
Novamind Announces DTC Eligibility for its Common Shares
Novamind announces that its shares are now eligible for electronic clearing through the DTC.
Are Psychedelic Stocks About To Heat Up (Again)?
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.
The Mental Health Crisis and Psychedelics: Big Business Targets The Sector
Psychedelic medicine is the solution to the Mental Health Crisis. Psychedelic drugs are a huge commercial opportunity. Big Business moves in.
Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1
Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.
Small Pharma Successfully Completes Phase I Clinical Trial Of DMT In Combination With Supportive Psychotherapy
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.
AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
The Two-Pronged Psychedelics Solution To The Opioid Crisis
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
